{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:22:07Z","timestamp":1787887327639,"version":"build-2784847793"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009068","name":"University of Bern","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009068","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.msard.2025.106691","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T10:32:20Z","timestamp":1755253940000},"page":"106691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Risk stratification for disease reactivation after therapy de-escalation\/discontinuation in relapsing multiple sclerosis by the VIAADISC score"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0825-0851","authenticated-orcid":false,"given":"Gabriel","family":"Bsteh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Introcaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Gradl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Traxler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Barket","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"F\u00f6ttinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helly Noemi","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nik","family":"Krajnc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ponleitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Zrzavy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Deisenhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska Di","family":"Pauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hoepner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Hegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2025.106691_bib0033","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients","volume":"79","author":"Alping","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106691_bib0004","first-page":"awae409","article-title":"De-escalating and discontinuing disease-modifying therapies in multiple sclerosis and related disorders","author":"Androdias","year":"2024","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.msard.2025.106691_bib0034","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1007\/s00415-021-10950-7","article-title":"Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study","volume":"269","author":"Bigaut","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106691_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.766956","article-title":"Estimating risk of Multiple sclerosis disease reactivation in pregnancy and postpartum: the VIPRiMS score","volume":"12","author":"Bsteh","year":"2022","journal-title":"Front. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2025.106691_bib0007","article-title":"Discontinuation of disease-modifying therapies in multiple sclerosis - clinical outcome and prognostic factors","volume":"7","author":"Bsteh","year":"2016","journal-title":"Mult. Scler. J."},{"issue":"7","key":"10.1016\/j.msard.2025.106691_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158978","article-title":"Long term clinical prognostic factors in relapsing-remitting multiple sclerosis: insights from a 10-year observational study","volume":"11","author":"Bsteh","year":"2016","journal-title":"PLoS. One"},{"issue":"5","key":"10.1016\/j.msard.2025.106691_bib0011","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/ene.14705","article-title":"Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: the VIAADISC score","volume":"28","author":"Bsteh","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106691_bib0012","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209752","article-title":"Association of disease-modifying treatment with outcome in patients with relapsing multiple sclerosis and isolated MRI activity","author":"Bsteh","year":"2024","journal-title":"Neurology."},{"issue":"5","key":"10.1016\/j.msard.2025.106691_bib0027","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200152","article-title":"Efficacy of Rituximab outlasts B-cell repopulation in multiple sclerosis: time to rethink dosing?","volume":"10","author":"Claverie","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflammation."},{"key":"10.1016\/j.msard.2025.106691_bib0031","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.msard.2018.02.028","article-title":"Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: a multicenter retrospective observational study (STRATEGY)","volume":"22","author":"Cohan","year":"2018","journal-title":"Mult Scler Relat Dis"},{"issue":"4","key":"10.1016\/j.msard.2025.106691_bib0032","article-title":"The results of a 24-month controlled, prospective study of relapsing multiple sclerosis patients at risk for progressive multifocal encephalopathy, who switched from prolonged use of natalizumab to teriflunomide","volume":"7","author":"Cohan","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"4","key":"10.1016\/j.msard.2025.106691_bib0037","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1001\/jamaneurol.2013.6240","article-title":"Switching from Natalizumab to Fingolimod in multiple sclerosis: a French prospective study","volume":"71","author":"Cohen","year":"2014","journal-title":"JAMa Neurol."},{"issue":"7","key":"10.1016\/j.msard.2025.106691_bib0010","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","article-title":"Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial","volume":"22","author":"Corboy","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106691_bib0019","series-title":"The Prevention and Treatment of Missing Data in Clinical Trials","year":"2010"},{"issue":"1","key":"10.1016\/j.msard.2025.106691_bib0026","article-title":"Sustained low relapse rate with highly variable B-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis","volume":"10","author":"Cucuzza","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"issue":"3","key":"10.1016\/j.msard.2025.106691_bib0038","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200231","article-title":"Effect of prior treatment with Fingolimod on early and late response to Rituximab\/Ocrelizumab in patients with multiple sclerosis","volume":"11","author":"Graille-Avy","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"3","key":"10.1016\/j.msard.2025.106691_bib0008","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1212\/CON.0000000000000738","article-title":"Monitoring, switching, and stopping multiple sclerosis disease-modifying therapies","volume":"25","author":"Gross","year":"2019","journal-title":"Continuum (N. Y.)"},{"issue":"4","key":"10.1016\/j.msard.2025.106691_bib0003","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/WCO.0000000000000960","article-title":"Stopping disease-modifying therapy in relapsing and progressive multiple sclerosis","volume":"34","author":"Hartung","year":"2021","journal-title":"Curr. Opin. Neurol."},{"issue":"Suppl. 3","key":"10.1016\/j.msard.2025.106691_bib0018","article-title":"\u2018No evidence of disease activity\u2019 - is it an appropriate surrogate in multiple sclerosis?","volume":"359","author":"Hegen","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106691_bib0016","series-title":"Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg.), Leitlinien f\u00fcr Diagnostik Und Therapie in Der Neurologie","article-title":"Diagnose und therapie der multiplen sklerose, neuromyelitis-optica-spektrum-erkrankungen und MOG-IgG-assoziierten erkrankungen, S2k-leitlinie","author":"Hemmer","year":"2023"},{"issue":"5","key":"10.1016\/j.msard.2025.106691_bib0020","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1177\/1352458518765656","article-title":"Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60","volume":"25","author":"Hua","year":"2018","journal-title":"Mult. Scler. J."},{"issue":"11","key":"10.1016\/j.msard.2025.106691_bib0030","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1093\/brain\/awv260","article-title":"Fingolimod versus interferon beta\/glatiramer acetate after natalizumab suspension in multiple sclerosis","volume":"138","author":"Iaffaldano","year":"2015","journal-title":"Brain"},{"issue":"10422","key":"10.1016\/j.msard.2025.106691_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)01473-3","article-title":"Multiple sclerosis","volume":"403","author":"Jakimovski","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.msard.2025.106691_bib0009","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamaneurol.2024.0395","article-title":"High-efficacy therapy discontinuation vs continuation in patients 50 years and older with nonactive MS","volume":"81","author":"Jouvenot","year":"2024","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2025.106691_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101468","article-title":"Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity","volume":"37","author":"Juto","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106691_bib0006","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2016-313760","article-title":"Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study","author":"Kister","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatr"},{"issue":"9","key":"10.1016\/j.msard.2025.106691_bib0017","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/brain\/aww173","article-title":"Defining secondary progressive multiple sclerosis","volume":"139","author":"Lorscheider","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106691_bib0036","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419887596","article-title":"Therapy with cladribine is efficient and safe in patients previously treated with natalizumab","volume":"12","author":"M\u00f6hn","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"4","key":"10.1016\/j.msard.2025.106691_bib0029","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40261-022-01129-7","article-title":"Multiple sclerosis relapses following cessation of Fingolimod","volume":"42","author":"Malpas","year":"2022","journal-title":"Clin. Drug Investig."},{"issue":"2","key":"10.1016\/j.msard.2025.106691_bib0022","doi-asserted-by":"crossref","first-page":"e960","DOI":"10.1212\/NXI.0000000000000960","article-title":"Defining benign\/burnt-out MS and discontinuing disease-modifying therapies","volume":"8","author":"McFaul","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2025.106691_bib0024","article-title":"Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies","author":"McGinley","year":"2019","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106691_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.811518","article-title":"Molecular mechanisms of immunosenescene and inflammaging: relevance to the immunopathogenesis and treatment of multiple sclerosis","volume":"12","author":"Perdaens","year":"2022","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2025.106691_bib0013","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria","volume":"58","author":"Polman","year":"2005","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106691_bib0014","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106691_bib0039","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419837809","article-title":"Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis","volume":"12","author":"Prosperini","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"17","key":"10.1016\/j.msard.2025.106691_bib0023","doi-asserted-by":"crossref","first-page":"e1926","DOI":"10.1212\/WNL.0000000000201029","article-title":"Disease reactivation after cessation of Disease-modifying therapy in patients with relapsing-remitting multiple sclerosis","volume":"99","author":"Roos","year":"2022","journal-title":"Neurology."},{"issue":"1\u20132","key":"10.1016\/j.msard.2025.106691_bib0005","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jns.2011.01.016","article-title":"Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity","volume":"303","author":"Siger","year":"2011","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.msard.2025.106691_bib0015","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106691_bib0021","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.msard.2019.07.021","article-title":"Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: effect on clinical and MRI outcomes","volume":"35","author":"Yano","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106691_bib0028","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000012084","article-title":"Natalizumab, Fingolimod and dimethyl fumarate use and pregnancy-related relapse and disability in women with multiple sclerosis","author":"Yeh","year":"2021","journal-title":"Neurology."},{"issue":"12","key":"10.1016\/j.msard.2025.106691_bib0035","first-page":"1330","article-title":"Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis","volume":"93","author":"Zhu","year":"2022","journal-title":"J Neurology Neurosurg Psychiatry"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500433X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500433X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:15:47Z","timestamp":1774998947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482500433X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":41,"alternative-id":["S221103482500433X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106691","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk stratification for disease reactivation after therapy de-escalation\/discontinuation in relapsing multiple sclerosis by the VIAADISC score","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106691","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106691"}}